WallStreetZenWallStreetZen

NASDAQ: ELDN
Eledon Pharmaceuticals Inc Stock

$2.36-0.21 (-8.17%)
Updated Mar 24, 2023
ELDN Price
$2.36
Fair Value Price
$6.98
Market Cap
$32.47M
52 Week Low
$1.90
52 Week High
$4.15
P/E
-0.88x
P/B
0.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.39M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$28M
Beta
0.55
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ELDN Overview

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELDN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ELDN ($2.36) is undervalued by 66.18% relative to our estimate of its Fair Value price of $6.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ELDN ($2.36) is significantly undervalued by 66.18% relative to our estimate of its Fair Value price of $6.98 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ELDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELDN due diligence checks available for Premium users.

Be the first to know about important ELDN news, forecast changes, insider trades & much more!

ELDN News

Valuation

ELDN fair value

Fair Value of ELDN stock based on Discounted Cash Flow (DCF)
Price
$2.36
Fair Value
$6.98
Undervalued by
66.18%
ELDN ($2.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELDN ($2.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ELDN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.88x
Industry
17.88x
Market
21.37x

ELDN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.23x
Industry
4.89x
ELDN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ELDN's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.5M
Profit Margin
0%
ELDN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$149.6M
Liabilities
$8.5M
Debt to equity
0.06
ELDN's short-term assets ($67.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELDN's short-term assets ($67.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELDN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELDN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.6M
Investing
$0.0
Financing
$0.0
ELDN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ELDN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ELDN$32.47M-8.06%-0.88x0.23x
AXLA$32.51M+0.45%-0.26x-4.30x
IMPL$32.29M+3.82%-0.31x-1.45x
MIRO$31.98M0.00%-1.16x0.98x
MEIP$31.98M-4.00%-1.04x0.66x

Eledon Pharmaceuticals Stock FAQ

What is Eledon Pharmaceuticals's quote symbol?

NASDAQ: ELDN) Eledon Pharmaceuticals trades on the NASDAQ under the ticker symbol ELDN. Eledon Pharmaceuticals stock quotes can also be displayed as NASDAQ: ELDN.

If you're new to stock investing, here's how to buy Eledon Pharmaceuticals stock.

What is the 52 week high and low for Eledon Pharmaceuticals (NASDAQ: ELDN)?

(NASDAQ: ELDN) Eledon Pharmaceuticals's 52-week high was $4.15, and its 52-week low was $1.90. It is currently -43.13% from its 52-week high and 24.21% from its 52-week low.

How much is Eledon Pharmaceuticals stock worth today?

(NASDAQ: ELDN) Eledon Pharmaceuticals currently has 13,756,788 outstanding shares. With Eledon Pharmaceuticals stock trading at $2.36 per share, the total value of Eledon Pharmaceuticals stock (market capitalization) is $32.47M.

Eledon Pharmaceuticals stock was originally listed at a price of $3,849.12 in Sep 17, 2014. If you had invested in Eledon Pharmaceuticals stock at $3,849.12, your return over the last 8 years would have been -99.94%, for an annualized return of -60.33% (not including any dividends or dividend reinvestments).

How much is Eledon Pharmaceuticals's stock price per share?

(NASDAQ: ELDN) Eledon Pharmaceuticals stock price per share is $2.36 today (as of Mar 24, 2023).

What is Eledon Pharmaceuticals's Market Cap?

(NASDAQ: ELDN) Eledon Pharmaceuticals's market cap is $32.47M, as of Mar 27, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Eledon Pharmaceuticals's market cap is calculated by multiplying ELDN's current stock price of $2.36 by ELDN's total outstanding shares of 13,756,788.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.